UBS Group AG Has $2.68 Million Stock Holdings in MediWound Ltd. $MDWD

UBS Group AG raised its stake in MediWound Ltd. (NASDAQ:MDWD) by 90.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 145,057 shares of the biopharmaceutical company’s stock after buying an additional 68,756 shares during the quarter. UBS Group AG owned 1.13% of MediWound worth $2,678,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd acquired a new position in MediWound in the 3rd quarter valued at approximately $1,042,000. Menora Mivtachim Holdings LTD. boosted its holdings in shares of MediWound by 348.8% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company’s stock worth $1,415,000 after buying an additional 61,039 shares during the period. Rosalind Advisors Inc. boosted its holdings in shares of MediWound by 84.0% during the 3rd quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company’s stock worth $13,498,000 after buying an additional 341,993 shares during the period. R Squared Ltd bought a new stake in shares of MediWound during the 3rd quarter worth $194,000. Finally, BNP Paribas Financial Markets boosted its holdings in MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 723 shares during the period. Institutional investors and hedge funds own 46.83% of the company’s stock.

MediWound Stock Up 0.6%

Shares of MediWound stock opened at $16.68 on Wednesday. The stock has a market capitalization of $214.34 million, a P/E ratio of -7.94 and a beta of 0.21. MediWound Ltd. has a 12-month low of $14.90 and a 12-month high of $22.50. The company has a 50-day simple moving average of $16.79 and a 200 day simple moving average of $17.51.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter. The company had revenue of $1.87 million during the quarter. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. On average, equities analysts anticipate that MediWound Ltd. will post -2.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MDWD. Wall Street Zen downgraded shares of MediWound from a “hold” rating to a “strong sell” rating in a report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $35.00.

MediWound Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.